Skip to main content

Table 1

From: Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

 

Wk 12

Wk 52

Responses

Placebo (n=37)

TCZ (n=75)

TCZ (n=88)

JIA ACR30 + absence of fever, n (%)

9 (24)

64 (85)

77 (88)

JIA ACR70, n (%)

3 (8)

53 (71)

78 (89)

JIA ACR90, n (%)

2 (5)

28 (37)

57 (65)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096